牛牛AI助理已提取核心訊息
On February 12, 2024, AbbVie Inc. announced the successful completion of its acquisition of ImmunoGen, Inc., a move that adds the flagship antibody-drug conjugate ELAHERE for ovarian cancer to AbbVie's portfolio. The acquisition is expected to be accretive to AbbVie’s earnings per share (EPS) starting in 2027 and is anticipated to contribute significantly to long-term revenue growth. AbbVie has updated its first-quarter adjusted diluted EPS guidance for 2024 to $2.26-$2.30, reflecting a $0.04 per share impact from the acquisition. The full-year adjusted diluted EPS guidance remains at $11.05-$11.25, now including a $0.42 per share impact from both the ImmunoGen and the pending Cerevel Therapeutics acquisitions. ImmunoGen's common stock is expected to cease trading on the NASDAQ prior to market open on February 12, 2024. The acquisition enhances AbbVie's oncology pipeline with ImmunoGen's late-stage development programs and investigational assets, such as IMGN-151 and pivekimab sunirine, which have the potential to transform treatment across various solid tumors and hematologic malignancies.
On February 12, 2024, AbbVie Inc. announced the successful completion of its acquisition of ImmunoGen, Inc., a move that adds the flagship antibody-drug conjugate ELAHERE for ovarian cancer to AbbVie's portfolio. The acquisition is expected to be accretive to AbbVie’s earnings per share (EPS) starting in 2027 and is anticipated to contribute significantly to long-term revenue growth. AbbVie has updated its first-quarter adjusted diluted EPS guidance for 2024 to $2.26-$2.30, reflecting a $0.04 per share impact from the acquisition. The full-year adjusted diluted EPS guidance remains at $11.05-$11.25, now including a $0.42 per share impact from both the ImmunoGen and the pending Cerevel Therapeutics acquisitions. ImmunoGen's common stock is expected to cease trading on the NASDAQ prior to market open on February 12, 2024. The acquisition enhances AbbVie's oncology pipeline with ImmunoGen's late-stage development programs and investigational assets, such as IMGN-151 and pivekimab sunirine, which have the potential to transform treatment across various solid tumors and hematologic malignancies.
2024年2月12日，艾伯維公司宣佈成功完成對ImmunoGen, Inc. 的收購，此舉將針對卵巢癌的旗艦抗體藥物偶聯物ELAHERE添加到艾伯維的投資組合中。從2027年開始，此次收購預計將增加AbbVie的每股收益（EPS），並有望爲長期收入增長做出重大貢獻。艾伯維已將其2024年第一季度調整後的攤薄每股收益預期更新至2.26美元至2.30美元，反映了此次收購對每股0.04美元的影響。調整後的全年攤薄後每股收益預期仍爲11.05-11.25美元，現在包括ImmunoGen和即將進行的Cerevel Therapeutics收購對每股0.42美元的影響。預計ImmunoGen的普通股將在2024年2月12日開市前停止在納斯達克的交易。此次收購通過ImmunoGen的後期開發計劃和研究資產（例如 IMGN-151 和pivekimab sunirine）增強了艾伯維的腫瘤產品線，這些資產有可能改變各種實體瘤和血液系統惡性腫瘤的治療方式。
2024年2月12日，艾伯維公司宣佈成功完成對ImmunoGen, Inc. 的收購，此舉將針對卵巢癌的旗艦抗體藥物偶聯物ELAHERE添加到艾伯維的投資組合中。從2027年開始，此次收購預計將增加AbbVie的每股收益（EPS），並有望爲長期收入增長做出重大貢獻。艾伯維已將其2024年第一季度調整後的攤薄每股收益預期更新至2.26美元至2.30美元，反映了此次收購對每股0.04美元的影響。調整後的全年攤薄後每股收益預期仍爲11.05-11.25美元，現在包括ImmunoGen和即將進行的Cerevel Therapeutics收購對每股0.42美元的影響。預計ImmunoGen的普通股將在2024年2月12日開市前停止在納斯達克的交易。此次收購通過ImmunoGen的後期開發計劃和研究資產（例如 IMGN-151 和pivekimab sunirine）增強了艾伯維的腫瘤產品線，這些資產有可能改變各種實體瘤和血液系統惡性腫瘤的治療方式。
有用
沒用